Pliant Other Assets vs Capital Lease Obligations Analysis

PLRX Stock  USD 13.49  0.15  1.12%   
Pliant Therapeutics financial indicator trend analysis is much more than just breaking down Pliant Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pliant Therapeutics is a good investment. Please check the relationship between Pliant Therapeutics Other Assets and its Capital Lease Obligations accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pliant Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Pliant Stock please use our How to Invest in Pliant Therapeutics guide.

Other Assets vs Capital Lease Obligations

Other Assets vs Capital Lease Obligations Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pliant Therapeutics Other Assets account and Capital Lease Obligations. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Pliant Therapeutics' Other Assets and Capital Lease Obligations is -0.05. Overlapping area represents the amount of variation of Other Assets that can explain the historical movement of Capital Lease Obligations in the same time period over historical financial statements of Pliant Therapeutics, assuming nothing else is changed. The correlation between historical values of Pliant Therapeutics' Other Assets and Capital Lease Obligations is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Assets of Pliant Therapeutics are associated (or correlated) with its Capital Lease Obligations. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Lease Obligations has no effect on the direction of Other Assets i.e., Pliant Therapeutics' Other Assets and Capital Lease Obligations go up and down completely randomly.

Correlation Coefficient

-0.05
Relationship DirectionNegative 
Relationship StrengthInsignificant

Other Assets

Capital Lease Obligations

Pliant Therapeutics capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Pliant Therapeutics asset purchases. For example, Pliant Therapeutics can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Pliant Therapeutics control over an asset for a big portion of its life. The total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee.
Most indicators from Pliant Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pliant Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pliant Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Pliant Stock please use our How to Invest in Pliant Therapeutics guide.At this time, Pliant Therapeutics' Sales General And Administrative To Revenue is fairly stable compared to the past year. Enterprise Value is likely to rise to about 1.1 B in 2024, whereas Selling General Administrative is likely to drop slightly above 29.4 M in 2024.
 2021 2022 2023 2024 (projected)
Interest Income272K4.7M20.5M21.5M
Net Interest Income272K3.9M19.2M20.2M

Pliant Therapeutics fundamental ratios Correlations

0.90.990.780.95-0.960.690.661.00.530.311.00.890.60.760.920.50.470.60.3-0.260.980.93-0.760.380.9
0.90.880.790.89-0.910.720.610.890.390.310.90.980.660.920.990.630.620.710.31-0.190.910.95-0.730.610.97
0.990.880.690.98-0.950.690.540.990.460.140.990.90.570.760.910.510.540.560.17-0.390.990.89-0.840.380.9
0.780.790.690.68-0.680.590.940.770.690.70.770.710.760.60.780.490.30.640.50.190.680.84-0.50.460.8
0.950.890.980.68-0.910.630.490.950.470.070.950.920.60.790.90.590.660.610.07-0.410.970.87-0.90.490.93
-0.96-0.91-0.95-0.68-0.91-0.74-0.56-0.96-0.31-0.26-0.96-0.9-0.57-0.84-0.92-0.54-0.51-0.63-0.280.33-0.98-0.90.72-0.43-0.89
0.690.720.690.590.63-0.740.510.690.130.140.690.710.60.520.680.260.250.340.23-0.390.660.69-0.620.260.69
0.660.610.540.940.49-0.560.510.650.720.850.660.490.670.370.610.28-0.030.50.690.40.510.73-0.250.240.61
1.00.890.990.770.95-0.960.690.650.520.31.00.890.590.760.920.490.470.590.29-0.270.980.92-0.760.370.9
0.530.390.460.690.47-0.310.130.720.520.520.530.360.370.10.450.06-0.080.230.530.410.380.6-0.270.00.46
0.310.310.140.70.07-0.260.140.850.30.520.30.160.350.180.320.08-0.280.340.80.70.170.440.240.080.24
1.00.90.990.770.95-0.960.690.661.00.530.30.890.590.760.920.490.470.590.29-0.260.980.93-0.760.370.9
0.890.980.90.710.92-0.90.710.490.890.360.160.890.560.910.980.570.680.610.18-0.340.920.92-0.790.540.95
0.60.660.570.760.6-0.570.60.670.590.370.350.590.560.540.590.790.370.850.250.060.560.64-0.610.770.76
0.760.920.760.60.79-0.840.520.370.760.10.180.760.910.540.890.750.780.770.11-0.280.850.78-0.660.730.87
0.920.990.910.780.9-0.920.680.610.920.450.320.920.980.590.890.560.580.660.35-0.180.930.97-0.710.520.96
0.50.630.510.490.59-0.540.260.280.490.060.080.490.570.790.750.560.730.95-0.09-0.120.580.48-0.620.970.71
0.470.620.540.30.66-0.510.25-0.030.47-0.08-0.280.470.680.370.780.580.730.55-0.49-0.580.610.39-0.770.720.64
0.60.710.560.640.61-0.630.340.50.590.230.340.590.610.850.770.660.950.550.230.10.630.64-0.530.920.78
0.30.310.170.50.07-0.280.230.690.290.530.80.290.180.250.110.35-0.09-0.490.230.730.160.520.29-0.070.25
-0.26-0.19-0.390.19-0.410.33-0.390.4-0.270.410.7-0.26-0.340.06-0.28-0.18-0.12-0.580.10.73-0.38-0.020.63-0.05-0.2
0.980.910.990.680.97-0.980.660.510.980.380.170.980.920.560.850.930.580.610.630.16-0.380.89-0.810.460.91
0.930.950.890.840.87-0.90.690.730.920.60.440.930.920.640.780.970.480.390.640.52-0.020.89-0.630.440.94
-0.76-0.73-0.84-0.5-0.90.72-0.62-0.25-0.76-0.270.24-0.76-0.79-0.61-0.66-0.71-0.62-0.77-0.530.290.63-0.81-0.63-0.55-0.82
0.380.610.380.460.49-0.430.260.240.370.00.080.370.540.770.730.520.970.720.92-0.07-0.050.460.44-0.550.68
0.90.970.90.80.93-0.890.690.610.90.460.240.90.950.760.870.960.710.640.780.25-0.20.910.94-0.820.68
Click cells to compare fundamentals

Pliant Therapeutics Account Relationship Matchups

Pliant Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets119.1M295.5M221.2M350.6M512.2M537.8M
Total Current Liabilities8.2M11.6M16.8M23.9M28.5M15.3M
Total Stockholder Equity(435K)283.1M199.1M313.3M473.6M497.3M
Net Tangible Assets(76.3M)283.1M199.1M313.3M360.3M378.4M
Retained Earnings(76.3M)(117.8M)(215.1M)(338.4M)(499.7M)(474.8M)
Accounts Payable1.3M2.0M3.0M1.6M4.5M2.6M
Cash85.8M50.9M51.7M33.7M63.2M55.1M
Cash And Short Term Investments102.8M276.9M200.6M331.2M494.2M519.0M
Net Receivables7.4M9.4M2.0M2.0M3.0M3.8M
Total Liab119.5M12.5M22.2M37.3M38.6M34.4M
Total Current Assets111.9M290.8M209.4M340.3M505.5M530.8M
Property Plant Equipment4.1M4.3M10.9M4.5M5.2M5.5M
Short Long Term Debt Total444K283K7.2M15.8M11.4M6.5M
Other Current Liab6.9M9.6M10.1M17.4M21.4M12.4M
Property Plant And Equipment Net4.1M4.3M10.9M9.9M4.8M7.0M
Net Debt(85.4M)(50.6M)(44.5M)(17.9M)(51.9M)(54.5M)
Non Current Assets Total7.2M4.8M11.8M10.3M6.7M8.3M
Non Currrent Assets Other3.1M451K838K394K1.9M957.1K
Other Assets3.1M451K838K394K1.00.95
Common Stock Shares Outstanding35.6M35.6M35.8M42.0M58.7M41.1M
Short Term Investments17.0M226.0M148.9M297.5M431.0M452.6M
Liabilities And Stockholders Equity119.1M295.5M221.2M350.6M512.2M286.9M
Non Current Liabilities Total111.3M866K5.3M13.4M10.1M9.6M
Capital Lease Obligations444K283K7.2M5.9M1.3M1.3M
Other Current Assets1.7M4.5M6.8M7.1M8.3M5.3M
Other Stockholder Equity2.2M400.9M414.3M653.7M973.0M1.0B
Net Invested Capital(76.3M)283.1M199.1M323.3M483.6M507.8M
Accumulated Other Comprehensive Income(1K)(32K)(201K)(2.0M)345K362.3K
Non Current Liabilities Other10K2K5.3M3.4M3.9M4.1M
Net Working Capital103.7M279.2M192.6M316.4M477.0M261.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Pliant Stock Analysis

When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.